Abcam PLC (ABCM)

Market Cap	3.56B
Revenue (ttm)	427.32M
Net Income (ttm)	41.10M
Shares Out	228.88M
EPS (ttm)	0.08
PE Ratio	194.00
Forward PE	31.85
Dividend	n/a
Ex-Dividend Date	n/a

Volume	796,674
Open	15.38
Previous Close	15.51
Day's Range	14.89 - 15.56
52-Week Range	12.54 - 24
Beta	0.46
Analysts	Buy
Price Target	20.23 (+30.3%)
Earnings Date	Sep 12, 2022

About ABCM

Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and rese...

• Industry: Biotechnology
• IPO Date: Oct 22, 2020
• CEO: Murray Hennessy
• Employees: 1,682
• Stock Exchange: NASDAQ
• Ticker Symbol: ABCM

Financial Performance

In 2021, Abcam's revenue was 315.40 million, an increase of 21.31% compared to the previous year's 260.00 million. Earnings were 4.40 million, a decrease of -64.80%.

Financial numbers in GBP

Analyst Forecast

According to 15 analysts, the average rating for ABCM stock is "Buy." The 12-month stock price forecast is 20.23, which is an increase of 30.35% from the latest price.

Price Target

$20.23

(30.35% upside)

Analyst Consensus: Buy